Advertisement
Canada markets open in 3 hours

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7313
    +0.0015 (+0.20%)
     

  • CRUDE OIL

    82.84
    +0.03 (+0.04%)
     

  • Bitcoin CAD

    86,876.34
    -3,923.71 (-4.32%)
     

  • CMC Crypto 200

    1,355.59
    -26.99 (-1.95%)
     

  • GOLD FUTURES

    2,337.50
    -0.90 (-0.04%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,502.25
    -162.25 (-0.92%)
     

  • VOLATILITY

    16.17
    +0.20 (+1.25%)
     

  • FTSE

    8,086.32
    +45.94 (+0.57%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6812
    -0.0007 (-0.10%)
     

Coronavirus latest: Monday, June 1

Yahoo Finance Video
Updated

As protests over the George Floyd case continue to grow, worries over the spread of coronavirus weigh heavily on medical experts as Gilead Sciences and Eli Lilly announce news about their vaccine trials. Yahoo Finance’s Anjalee Khemlani joins The Final Round to break down the latest news about the coronavirus.

Video Transcript

MYLES UDLAND: All right, let's switch gears a little bit and talk a bit about what's going on as it relates to the pandemic, COVID-19, and the coronavirus. Some treatment news coming out earlier today. Anjalee Khemlani joins us now for the latest. Anjalee?

ANJALEE KHEMLANI: Thanks, Myles. Yep, so on the treatment news, we do know about Gilead Sciences and the remdesivir, that antiviral that they have been testing. We did hear that positive news earlier last month basically. But we actually got back clinical trial data out. And so that has been something to just look through in terms of the exact details.

ADVERTISEMENT

But most of what we already knew earlier still stands true, in terms of five days is still a very effective timespan when being treated. The company is still expanding its trial to ensure that they actually test this on those individuals that are also on ventilators, which hasn't been done. And these are individuals with moderate symptoms as well.

And so also, we heard about Eli Lilly, which is starting at the first human trials of a plasma therapy treatment. And that's something that's really interesting, because we know that so much has been made about the antibodies that some people have produced when they've recovered from this virus, and what that potential has for sharing among those who need treatment for it. And so we've seen at the hospital level where they have these straight transfers from the donations.

But now we're looking at a way to really cultivate that. And that's what Eli Lilly is doing in its partnership with Vancouver-based AbCellera.

MYLES UDLAND: All right, Anjalee Khemlani with the latest on the treatment front. We'll talk to you in the next hour.